HomeCompareEART vs JNJ

EART vs JNJ: Dividend Comparison 2026

EART yields 0.60% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EART wins by $499.00 in total portfolio value
10 years
EART
EART
● Live price
0.60%
Share price
$29.86
Annual div
$0.18
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.5K
Annual income
$62.76
Full EART calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — EART vs JNJ

📍 EART pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEARTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EART + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EART pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EART
Annual income on $10K today (after 15% tax)
$51.29/yr
After 10yr DRIP, annual income (after tax)
$53.35/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $650.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EART + JNJ for your $10,000?

EART: 50%JNJ: 50%
100% JNJ50/50100% EART
Portfolio after 10yr
$20.3K
Annual income
$445.27/yr
Blended yield
2.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EART
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EART buys
0
JNJ buys
0
No recent congressional trades found for EART or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEARTJNJ
Forward yield0.60%3.36%
Annual dividend / share$0.18$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$20.5K$20.0K
Annual income after 10y$62.76$827.78
Total dividends collected$617.00$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EART vs JNJ ($10,000, DRIP)

YearEART PortfolioEART Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,760$60.35$10,676$355.77+$84.00EART
2$11,574$60.69$11,407$389.39+$167.00EART
3$12,445$61.01$12,198$426.53+$247.00EART
4$13,378$61.31$13,056$467.62+$322.00EART
5$14,376$61.59$13,987$513.12+$389.00EART
6$15,444$61.85$14,998$563.56+$446.00EART
7$16,587$62.10$16,098$619.52+$489.00EART
8$17,811$62.34$17,295$681.69+$516.00EART
9$19,120$62.56$18,599$750.82+$521.00EART
10$20,521$62.76$20,022$827.78+$499.00EART

EART vs JNJ: Complete Analysis 2026

EARTStock

DMAT tracks an index of global stocks that produce metals and other raw materials essential to the expansion of disruptive technologies. Disruptive Materials Companies derive at least 50% of their revenues from the exploration, mining, production and/or enhancement of one or more of 10 materials categories that include Rare Earth Materials, Lithium, Copper, Carbon Fiber, etc. Stocks not meeting the revenue requirements are considered after review and recognized as Pre-Revenue Disruptive Materials Companies. In the case of Lithium, stocks with associated revenue between 25-50% are also eligible as Diversified Lithium Companies. The fund uses a natural language processing algorithm to identify and rank stocks. The five highest-ranked Disruptive Materials and Pre-Revenue Disruptive Materials Companies per materials category are selected. The fund employs a modified market-cap weighting scheme for diversification. The index is reconstituted and rebalanced semi-annually.

Full EART Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this EART vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EART vs SCHDEART vs JEPIEART vs OEART vs KOEART vs MAINEART vs ABBVEART vs MRKEART vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.